Drug pricing regulator National Pharmaceutical Pricing Authority (NPPA) has revised ceiling prices of 4 scheduled formulations of Scheduled-I under Drug (Price Control) Amendment Order, 2016 and retail price of one formulation under DPCO, 2013.The scheduled formulations are Clotrimazole cream 1%, Ceftriaxone Powder for Injection 1gm, Erythropoietin Injection 2000 IU/ml and Erythropoietin Injection 10000 IU/ml and Monocef-SB 125 mg Injection.
The Department of Pharmaceuticals (DoP) directive to the NPPA comes following complaints from several manufacturers that the NPPA is adopting a practice that even when some brands/generic versions of a medicine of a company have less than 1% market share, the market share of all such versions of that medicine of that company is clubbed together.
The leaked internal e-mails seem to show employees of one of the world's leading pharmaceutical companies calling for "celebrating" price rises for cancer drugs, a survey revealed.
When the pharmaceutical giant negotiated the price of pharmaceuticals in Spain, the pharmaceutical giant would have threatened to stop selling cancer treatments unless the Minister of Health agreed to price increases of up to 4,000 percent, The Spanish daily El Confidencial Digital said at the time. Price increases were made possible by a loophole that allows pharmaceutical companies to change the price of drugs if they are no longer branded with the same name.
The staff of Aspen Pharmacare, based in South Africa and having its European headquarters in Dublin, would have been traced to destroy stocks of life-saving drugs during a price conflict with the Spanish health service in 2014.
After buying five different cancer drugs from the British company GlaxoSmithKline (GSK), the company tried to sell drugs in Europe up to 40 times their previous price, The Times reported. In 2013, the price of a package of a chemotherapy drug called busulfan, used to treat leukemia, rose from £ 5.20 to £ 65.22 in England and Wales.
As a result of price restrictions imposed by the National Pharmaceutical Pricing Authority (NPPA), India's drug pricing regulator, earlier this year, many multinational stent manufacturers are considering withdrawing their products from high Range of the country by citing "non-viability".
Maharashtra Registered Pharmacists Association (MRPA) requested JP Nadda, union health minister to reconsider Union health ministry's proposal to empower Pharmacist (chemists) to supply alternative cheaper drugs (Generic) with same ingredients.
Prime Minister Narendra Modi said that world health surveys have re-established the importance of hygiene, no one has paid much attention to preventive measures in health care in India, Adding that the mission of his government Swachh Bharat is a part of promoting health habits
Indian PM Narendra Modi at the dedication ceremony of Kiran Multispeciality Hospital in Surat Prime Minister Narendra Modi said his government could adopt a legal framework whereby doctors will have to prescribe cheaper generic medicines than brand-name drugs equivalent to Patients. Modi said his government adopted a health policy after 15 years and limited the prices of drugs and stents, which angered some pharmaceutical companies.
National drug price regulator the National Pharmaceutical Pricing Authority (NPPA) has issued Guideline and Standard Operating Procedure for disposal of such review cases.
Health care spending has increased as the burden of critical illnesses such as cancer, diabetes and hypertension is constantly increasing, requiring patients to continue taking medications throughout their lives.
Food Safety and Standard Authority of India (FSSAI) a conclusion without agreement with the US company Decernis, which helps it access the database of more than 70,000 standards for food additives, food standards, Food and contaminants from more than 170 countries, said the organization in a statement.
Do Not Forget to Verify
(Click on Subscription link in your inbox)
--------
Also Join: 
.png)
